secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001193125-23-004050
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon prioritizes 4 flagship complement programs; GBS Phase 3 enrollment expanded to 220 patients
--------------------------------------------------------------------------------

- ANX005 Phase 3 in GBS expanded to 220 patients; pivotal data expected H1 2024.
- ANX005 Phase 2/3 pivotal in Huntington's to initiate in 2023.
- ANX007 Phase 2 in geographic atrophy on track for initial data mid-2023.
- Cash $269.5M as of Sep 30, 2022; operating runway updated to into 2025.
- Deprioritizing wAIHA; advancing ANX1502 (oral small molecule) into MAD study H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000119312523004050/0001193125-23-004050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000119312523004050/d422908d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-004050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer